Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin

Abstract

Background: The literature surrounding the risk of intraocular bleeding associated with novel oral anticoagulants (NOACs) compared to warfarin reveals a complex interplay of efficacy and safety outcomes.  Literature Review: The systematic review by (Sardar et al., 2013) highlighted the significant reduction in intracranial bleeding risks among NOAC users, which is particularly relevant for patients with atrial fibrillation and a history of stroke or transient ischemic attacks. Focusing specifically on intraocular bleeding, (Park et al., 2020) provided evidence that NOACs may exhibit a lower risk of intraocular bleeding in patients with retinal vascular diseases, particularly among those with diabetes. This suggests that NOACs could be a safer option in populations where intraocular bleeding is a concern. However, the study also emphasized the need for more targeted research to clarify these risks further. The investigations conducted in 2011 by (Reum Choe et al., 2011) and (Waranugraha et al., 2011) highlighted the complexities surrounding gastrointestinal bleeding, revealing inconsistent findings regarding the bleeding risks associated with NOACs compared to warfarin. This inconsistency underscores the need for a nuanced understanding of bleeding risks across different clinical settings and patient populations. Finally, (Liu et al., 2012) emphasized the variability in results regarding recurrent events and bleeding risks in real-world studies, indicating that while NOACs may offer certain advantages, the overall safety profile, particularly concerning intraocular bleeding, remains complex and warrants ongoing research. Conclusion: In conclusion, the literature demonstrates that NOACs generally present a lower risk of major bleeding events compared to warfarin, with specific advantages in reducing intracranial and potentially intraocular bleeding risks. However, the variability in bleeding risks across different studies and patient populations highlights the need for individualized treatment approaches and further research to establish clearer safety profiles for NOACs, particularly in the context of intraocular bleeding.